Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

CRVS holding history

Corvus Pharmaceuticals, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CRVS overviewAll 13F holders of CRVSFull Q2 2026 holdings

Shares (Q2 2026)
396,116
Value
$5.92M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of CRVS by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026396,116$5.92M<0.1%+107,002+37.0%AddedHolders
Q1 2026289,114$4.23M<0.1%+77,108+36.4%AddedHolders
Q4 2025212,006$1.63M<0.1%+49,932+30.8%AddedHolders
Q3 2025162,074$1.19M<0.1%+72,360+80.7%AddedHolders
Q2 202589,714$358.9K<0.1%+53,320+146.5%AddedHolders
Q1 202536,394$115.7K<0.1%−15,715−30.2%ReducedHolders
Q4 202452,109$278.8K<0.1%+36,428+232.3%AddedHolders
Q3 202415,681$82.8K<0.1%+2,681+20.6%AddedHolders
Q2 202413,000$23.7K<0.1%+8,321+177.8%AddedHolders
Q1 20244,679$8.33K<0.1%−2,021−30.2%ReducedHolders
Q4 20236,700$11.8K<0.1%00.0%UnchangedHolders
Q3 20236,700$9.78K<0.1%00.0%UnchangedHolders
Q2 20236,700$15.3K<0.1%−4,314−39.2%ReducedHolders
Q1 202311,014$10.0K<0.1%+6,314+134.3%AddedHolders
Q4 20224,700$4.00K<0.1%−17,956−79.3%ReducedHolders
Q3 202222,656$18.0K<0.1%+85+0.4%AddedHolders
Q2 202222,571$22.0K<0.1%+8,464+60.0%AddedHolders
Q1 202214,107$23.0K<0.1%+4,837+52.2%AddedHolders
Q4 20219,270$22.0K<0.1%+6,270+209.0%AddedHolders
Q3 20213,000$15.0K<0.1%00.0%UnchangedHolders
Q2 20213,000$8.00K<0.1%00.0%UnchangedHolders
Q1 20213,000$9.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.